NW Bio Enters First 180-Day Grace Period Relating To Non-Compliance With Nasdaq $1.00 Per Share Bid Requirement

[at noodls] – Progress Also Reported On Additional Nasdaq Compliance Issue BETHESDA, MD, June 30, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (‘NW Bio’), a U.S. biotechnology company developing DC…Read More »

5:43 pm Northwest Biotherapeutics receives Nasdaq notice pertaining to $1.00 per share bid requirement, updates on additional Nasdaq Compliance Issue

NW Bio Enters First 180-Day Grace Period Relating To Non-Compliance With Nasdaq $1.00 Per Share Bid Requirement

[PR Newswire] – On June 24, 2016, Northwest Biotherapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from Nasdaq Staff that the Company is not in compliance with Nasdaq Listing R…Read More »

NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

Forward Looking Statements

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the use of proceeds; the exercise of the Overallotment Right and the satisfaction of customary closing conditions for such exercise; the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company’s products will demonstrate safety and efficacy, risks related to the Company’s and Cognate’s abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company’s ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

This Blog is official and sanctioned by Northwest Biotherapeutics | See Disclaimer | See Privacy Policy

Get Northwest Biotherapeutics Blog Post Alerts